Role of P2X7 receptor in the progression and clinicopathological characteristics of gastric cancer.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Stomach Neoplasms*/pathology ; Stomach Neoplasms*/metabolism ; Stomach Neoplasms*/genetics ; Receptors, Purinergic P2X7*/metabolism ; Receptors, Purinergic P2X7*/genetics ; Cell Proliferation* ; Cell Movement* ; Disease Progression*; Humans ; Female ; Male ; Middle Aged ; Cell Line, Tumor ; Neoplasm Invasiveness ; Aged ; Lymphatic Metastasis ; Adenosine Triphosphate/metabolism ; Gene Expression Regulation, Neoplastic ; Neoplasm Staging

P2X7 receptor (P2X7R) plays a role in regulating tumor progression, but it is unclear whether P2X7R affects the pathological characteristics of patients with gastric cancer and the activity of gastric cancer cells. Therefore, this study preliminarily investigated the relationship between P2X7R and clinicopathological features of patients with gastric cancer, and further explored the effect of P2X7R on the proliferation, migration and invasion of gastric cancer cells through functional experiments. The results showed that P2X7R was highly expressed in gastric cancer tissues and gastric cancer cells. High expression of P2X7R was closely related to lymphatic metastasis, vascular invasion and Tumor-Node-Metastasis (TNM) stage in patients with gastric cancer. High expression of P2X7R predicted poor overall survival in patients. Moreover, the activation of P2X7R by ATP and its analogue BzATP increased the calcium current of gastric cancer cells, enhanced YF actin stress and cell viability, and promoted the proliferation, migration and invasion of gastric cancer cells. While P2X7R antagonists (A438079 and AZD9056) inhibited the proliferation, migration and invasion of gastric cancer cells induced by ATP. Therefore, the data obtained in this experiment suggest that P2X7R may be another potential molecular target for the prevention and treatment of gastric cancer.
Competing Interests: Declarations. Competing interests: The authors declare no competing interests. Ethical approval and consent to participate: Ethical approval has been exempted by the Ethics Committee of the Second Affiliated Hospital of Nanchang University. All protocols were approved by the Ethics Committee, China.
(© 2025. The Author(s).)

Exp Mol Med. 2004 Aug 31;36(4):358-66. (PMID: 15365255)
Physiol Rev. 2014 Jan;94(1):235-63. (PMID: 24382887)
J Cancer Res Clin Oncol. 2020 Nov;146(11):2731-2741. (PMID: 32892231)
Hum Pathol. 2017 Jun;64:61-68. (PMID: 28412208)
Purinergic Signal. 2023 Dec;19(4):685-697. (PMID: 36854856)
Adv Med Sci. 2019 Sep;64(2):388-394. (PMID: 31276917)
Cancer Res. 2012 Jun 15;72(12):2957-69. (PMID: 22505653)
Purinergic Signal. 2024 Mar 12;:. (PMID: 38470513)
Oncogene. 2015 Oct 8;34(41):5240-51. (PMID: 25619831)
Cell Death Dis. 2020 Oct 18;11(10):876. (PMID: 33071281)
Cells. 2021 Jul 29;10(8):. (PMID: 34440697)
Cancers (Basel). 2023 Apr 16;15(8):. (PMID: 37190249)
J Osteoporos. 2012;2012:637863. (PMID: 22970409)
PLoS One. 2014 Sep 16;9(9):e107224. (PMID: 25226385)
Oncogene. 2020 Aug;39(35):5795-5810. (PMID: 32724162)
Sci Rep. 2023 May 24;13(1):8435. (PMID: 37225786)
Front Oncol. 2024 Jan 11;13:1297775. (PMID: 38273855)
Cancers (Basel). 2020 Aug 19;12(9):. (PMID: 32825056)
Oncogene. 2011 May 5;30(18):2108-22. (PMID: 21242969)
Carcinogenesis. 2013 Jul;34(7):1487-96. (PMID: 23524196)
Purinergic Signal. 2021 Jun;17(2):179-200. (PMID: 33576905)
Cancer Sci. 2019 Aug;110(8):2456-2470. (PMID: 31148343)
Brain Res Bull. 2022 Sep;187:199-209. (PMID: 35850190)
Biochem Pharmacol. 2021 May;187:114350. (PMID: 33253643)
Cell Death Dis. 2021 Nov 16;12(12):1088. (PMID: 34789738)
Purinergic Signal. 2022 Mar;18(1):135-154. (PMID: 34964926)
Lancet. 2020 Aug 29;396(10251):635-648. (PMID: 32861308)
Methods Mol Biol. 2020;2101:371-385. (PMID: 31879914)
Purinergic Signal. 2020 Sep;16(3):327-336. (PMID: 32583309)
Front Pharmacol. 2021 Jan 27;11:617211. (PMID: 33584298)
Oncogene. 2019 May;38(19):3636-3650. (PMID: 30655604)
Biochem Biophys Res Commun. 2021 Jun 18;558:147-153. (PMID: 33915328)
Trends Cancer. 2021 Aug;7(8):731-750. (PMID: 34074623)
Eur J Pharmacol. 2021 May 15;899:174041. (PMID: 33737010)
EMBO J. 2021 Jul 1;40(13):e108130. (PMID: 34121201)
Purinergic Signal. 2023 Dec 28;:. (PMID: 38153612)
Cells. 2021 Jul 14;10(7):. (PMID: 34359950)
Eur J Med Chem. 2023 Dec 5;261:115877. (PMID: 37857146)

20224BAB216030 Youth Science Foundation of Jiangxi Province

Keywords: Clinicopathological features; Gastric cancer (GC); Migration and invasion; P2X7 receptor (P2X7R); Proliferation

0 (Receptors, Purinergic P2X7)
8L70Q75FXE (Adenosine Triphosphate)
0 (P2RX7 protein, human)

Date Created: 20241231 Date Completed: 20241231 Latest Revision: 20250104

20250104

PMC11685580

10.1038/s41598-024-81515-7

39738256